A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)

B Paes, I Mitchell, A Li, K L Lanctôt, CARESS Investigators, U Allen, G Bacheyie, A Bayliss, C Bjornson, M Blayney, A-M Canakis, R Canning, G Caouette, K Chang, L Chang, A Chiu, B DiGravio, J P Doray, M E Dumas, V Ho, C Hui, F Jagdis, M Lebel, D Lee, C Majaesic, I Margolis, M Mitchell, K O'Brien, C Ojah, A Papageorgiou, J Popovich, K Sankaran, B Simmons, D Stinson, Candice Bjornson, Georges Caouette, Marc Lebel, Mario Eddy Dumas, Charles Hui, Ann Bayliss, Bruno DiGravio, Jean-Pierre Doray, Dora Stinson, Apostolos Papageorgiou, Marianne Mitchell, Aaron Chiu, Bosco Paes, Roderick Canning, Anne-Marie Canakis, Karel O'Brien, Karen Chang, Koravangattu Sankaran, Vincent Ho, Upton Allen, Larry Chang, Cecil Ojah, David Lee, Carina Majaesic, Marc Blayney, Jelena Popovich, Frank Jagdis, Ivor Margolis, William Osler, Godfrey Bacheyie, Brian Simmons, B Paes, I Mitchell, A Li, K L Lanctôt, CARESS Investigators, U Allen, G Bacheyie, A Bayliss, C Bjornson, M Blayney, A-M Canakis, R Canning, G Caouette, K Chang, L Chang, A Chiu, B DiGravio, J P Doray, M E Dumas, V Ho, C Hui, F Jagdis, M Lebel, D Lee, C Majaesic, I Margolis, M Mitchell, K O'Brien, C Ojah, A Papageorgiou, J Popovich, K Sankaran, B Simmons, D Stinson, Candice Bjornson, Georges Caouette, Marc Lebel, Mario Eddy Dumas, Charles Hui, Ann Bayliss, Bruno DiGravio, Jean-Pierre Doray, Dora Stinson, Apostolos Papageorgiou, Marianne Mitchell, Aaron Chiu, Bosco Paes, Roderick Canning, Anne-Marie Canakis, Karel O'Brien, Karen Chang, Koravangattu Sankaran, Vincent Ho, Upton Allen, Larry Chang, Cecil Ojah, David Lee, Carina Majaesic, Marc Blayney, Jelena Popovich, Frank Jagdis, Ivor Margolis, William Osler, Godfrey Bacheyie, Brian Simmons

Abstract

We examined the dosing regimens, compliance, and outcomes of premature infants who received palivizumab within the Canadian Registry of Palivizumab (CARESS). Infants receiving ≥1 dose of palivizumab during the 2006-2011 respiratory syncytial virus (RSV) seasons were recruited across 30 sites. Respiratory illness events were captured monthly. Infants ≤32 completed weeks gestational age (GA) (Group 1) were compared to 33-35 completed weeks GA infants (Group 2) following prophylaxis. In total, 6,654 patients were analyzed (Group 1, n = 5,183; Group 2, n = 1,471). The mean GA was 29.9 ± 2.9 versus 34.2 ± 2.2 weeks for Groups 1 and 2, respectively. Group differences were significant (all p-values <0.05) for the following: proportion of males, Caucasians, siblings, multiple births, maternal smoking, smoking during pregnancy, household smokers, >5 household individuals, birth weight, and enrolment age. Overall, infants received 92.6 % of expected injections. Group 1 received significantly more injections, but a greater proportion of Group 2 received injections within recommended intervals. The hospitalization rates were similar for Groups 1 and 2 for respiratory illness (4.7 % vs. 3.7 %, p = 0.1) and RSV (1.5 % vs. 1.4 %, p = 0.3). Neither the time to first respiratory illness [hazard ratio = 0.9, 95 % confidence interval (CI) 0.7-1.2, p = 0.5] nor to first RSV hospitalization (hazard ratio = 1.3, 95 % CI 0.8-2.2, p = 0.3) were different. Compliance with RSV prophylaxis is high. Despite the higher number of palivizumab doses in infants ≤32 completed weeks GA, the two groups' respiratory illness and RSV-positive hospitalization rates were similar.

Figures

Fig. 1
Fig. 1
Cox proportional hazard curves depicting the effect of group allocation on the time to hospitalization for respiratory illness (a) and respiratory syncytial virus (RSV)-positive infection (b), comparing infants of ≤32 completed weeks gestational age (GA; solid lines) and those of 33–35 completed weeks GA (dotted lines). Group allocation did not have an effect in either case [respiratory illness: hazard ratio = 0.9, 95 % confidence interval (CI) 0.70–1.2, p = 0.5; RSV-positive infection: hazard ratio = 1.3, 95 % CI 0.8–2.2, p = 0.3]
Fig. 2
Fig. 2
Cox proportional hazard curves illustrating the number of risk factors that had a significant effect on the time to first RSV-positive hospitalization: having siblings, >5 individuals in the household, a history of atopy in the immediate family, and smoking in the household

References

    1. IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531–537. doi: 10.1542/peds.102.3.531.
    1. Committee on Infectious Diseases From the American Academy of Pediatrics: Policy statements—Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694–1701. doi: 10.1542/peds.2009-2345.
    1. Deutsche Gesellschaft für Pädiatrische Infektiologie (DGPI); Deutsche Gesellschaft für Pädiatrische Kardiologie (DGPK); Gesellschaft für Pädiatrische Pneumologie (GPP); Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin (GNPI) (2006) Stellungnahme zur Prophylaxe von schweren RSV-Erkrankungen bei Risikokindern mit Palivizumab. . Accessed January 2012
    1. Figueras Aloy J, Carbonell Estrany X, Comité de Estándares de la Sociedad Española de Neonatología Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation) An Pediatr (Barc) 2010;73(2):98.e1–98.e4. doi: 10.1016/j.anpedi.2010.05.026.
    1. Figueras Aloy J, Quero J, Doménech E, López Herrera MC, Izquierdo I, Losada A, Perapch J, Sánchez-Luna M, Comité de Estándares de la Sociedad Española de Neonatología Recommendations for the prevention of respiratory syncytial virus infection. An Pediatr (Barc) 2005;63(4):357–362. doi: 10.1157/13079818.
    1. Resch B, Berger A, Bernert G, Eber E, Frischer T, Simma B, Zacharasiewicz A, Zach M. Konsensuspapier zur prophylaxe der RSV-infektion mit palivizumab und post-RSV-atemwegserkrankung. Monatsschr Kinderheilkd. 2008;156:381–383. doi: 10.1007/s00112-008-1722-y.
    1. Robinson JL, Canadian Paediatric Society, Infectious Diseases and Immunization Committee Preventing respiratory syncytial virus infections. Paediatr Child Health. 2011;16(8):488–490.
    1. Rondini G, Macagno F, Barberi I. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS) Acta Neonatologica. 2004;1:1–11.
    1. Carbonell-Estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon JB, European RSV Risk Factor Study Group Validation of a model to predict hospitalization due to RSV of infants born at 33–35 weeks’ gestation. J Perinat Med. 2010;38(4):411–417. doi: 10.1515/jpm.2010.074.
    1. Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group Case–control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J. 2004;23(9):815–820. doi: 10.1097/01.inf.0000136869.21397.6b.
    1. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O’Brien K, Majaesic C, Caouette G, Frenette L, Le Saux N, Simmons B, Moisiuk S, Sankaran K, Ojah C, Singh AJ, Lebel MH, Bacheyie GS, Onyett H, Michaliszyn A, Manzi P, Parison D. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23(9):806–814. doi: 10.1097/.
    1. Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O’Brien K, Allen U, Mitchell I, Aloy JF, Pedraz C, Michaliszyn AF. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making. 2008;28(4):471–480. doi: 10.1177/0272989X08315238.
    1. Simões EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J, European RSV Risk Factor Study Group A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res. 2008;9:78. doi: 10.1186/1465-9921-9-78.
    1. Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M, European RSV Risk Factor Study Group European risk factors’ model to predict hospitalization of premature infants born 33–35 weeks’ gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med. 2011;24(1):152–157. doi: 10.3109/14767058.2010.482610.
    1. Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simões EA. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J. 2010;29(4):374–376.
    1. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143(5 Suppl):S133–S141.
    1. Law B, Macdonald N, Langley J, Mitchell I, Stephens D, Wang E, Robinson J, Boucher F, McDonald J, Dobson S. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent? Paediatr Child Health. 1998;3(6):402–404.
    1. Willson DF, Landrigan CP, Horn SD, Smout RJ. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr. 2003;143(5 Suppl):S142–S149.
    1. Mitchell I, Paes BA, Li A, Lanctôt KL, CARESS investigators CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J. 2011;30(8):651–655. doi: 10.1097/INF.0b013e31821146f7.
    1. Berner R, Schwoerer F, Schumacher RF, Meder M, Forster J. Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999. Eur J Pediatr. 2001;160(9):541–547. doi: 10.1007/s004310100801.
    1. Boyce TG, Mellen BG, Mitchel EF, Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137(6):865–870. doi: 10.1067/mpd.2000.110531.
    1. Meert K, Heidemann S, Abella B, Sarnaik A. Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med. 1990;18(12):1357–1359. doi: 10.1097/00003246-199012000-00009.
    1. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154(1):55–61.
    1. Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, Langley JM, McDonald J, MacDonald NE, Mitchell I. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1996;129(3):390–395. doi: 10.1016/S0022-3476(96)70071-9.
    1. Weigl JA, Puppe W, Schmitt HJ. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis. 2001;20(7):452–459.
    1. Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed. 2005;90(1):F64–F68. doi: 10.1136/adc.2003.029710.
    1. Damore D, Mansbach JM, Clark S, Ramundo M, Camargo CA., Jr Prospective multicenter bronchiolitis study: predicting intensive care unit admissions. Acad Emerg Med. 2008;15(10):887–894. doi: 10.1111/j.1553-2712.2008.00245.x.
    1. Kneyber MC, Brandenburg AH, de Groot R, Joosten KF, Rothbarth PH, Ott A, Moll HA. Risk factors for respiratory syncytial virus associated apnoea. Eur J Pediatr. 1998;157(4):331–335. doi: 10.1007/s004310050822.
    1. Ralston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr. 2009;155(5):728–733. doi: 10.1016/j.jpeds.2009.04.063.
    1. Schiller O, Levy I, Pollak U, Kadmon G, Nahum E, Schonfeld T. Central apnoeas in infants with bronchiolitis admitted to the paediatric intensive care unit. Acta Paediatr. 2011;100(2):216–219. doi: 10.1111/j.1651-2227.2010.02004.x.
    1. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143(5 Suppl):S150–S156.
    1. Méndez Rubio I, Lázaro de Mercado P, Carbonell Estrany X, Figueras Aloy J, Grupo IRIS Quality of life of preterm infants and admissions due to respiratory infections. An Pediatr (Barc) 2010;73(3):121–131. doi: 10.1016/j.anpedi.2009.10.010.
    1. Welliver RC, Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin. 2010;26(9):2175–2181. doi: 10.1185/03007995.2010.505126.
    1. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J. 2003;22(6):483–490.
    1. Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis. Curr Med Res Opin. 2008;24(11):3223–3237. doi: 10.1185/03007990802484234.
    1. Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood MA, Fitch Warner K. The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32–35 weeks in Spain. An Pediatr (Barc) 2006;65(4):316–324. doi: 10.1157/13092505.
    1. Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J. 2012;31(1):e1–e8. doi: 10.1097/INF.0b013e318235455b.
    1. Frogel M, Nerwen C, Cohen A, Vanveldhuisen P, Harrington M, Boron M, Palivizumab Outcomes Registry Group Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28(7):511–517. doi: 10.1038/jp.2008.28.
    1. Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30(6):510–517.
    1. Simões EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143(5 Suppl):S118–S126.
    1. Sommer C, Resch B, Simões EA. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J. 2011;5:144–154. doi: 10.2174/1874285801105010144.
    1. Al-Shehri MA, Sadeq A, Quli K. Bronchiolitis in Abha, Southwest Saudi Arabia: viral etiology and predictors for hospital admission. West Afr J Med. 2005;24(4):299–304.
    1. Carbonell-Estrany X, Quero J, IRIS Study Group Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001;20(9):874–879. doi: 10.1097/00006454-200109000-00010.
    1. von Linstow ML, Høgh M, Nordbø SA, Eugen-Olsen J, Koch A, Høgh B. A community study of clinical traits and risk factors for human metapneumovirus and respiratory syncytial virus infection during the first year of life. Eur J Pediatr. 2008;167(10):1125–1133. doi: 10.1007/s00431-007-0643-4.
    1. Semple MG, Taylor-Robinson DC, Lane S, Smyth RL. Household tobacco smoke and admission weight predict severe bronchiolitis in infants independent of deprivation: prospective cohort study. PLoS One. 2011;6(7):e22425. doi: 10.1371/journal.pone.0022425.
    1. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol. 1991;133(11):1135–1151.
    1. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, Munich RSV Study Group Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003;162(4):230–236.
    1. Sritippayawan S, Prapphal N, Wong P, Tosukhowong P, Samransamruajkit R, Deerojanawong J. Environmental tobacco smoke exposure and respiratory syncytial virus infection in young children hospitalized with acute lower respiratory tract infection. J Med Assoc Thai. 2006;89(12):2097–2103.
    1. Castro SM, Chakraborty K, Guerrero-Plata A. Cigarette smoke suppresses TLR-7 stimulation in response to virus infection in plasmacytoid dendritic cells. Toxicol In Vitro. 2011;25(5):1106–1113. doi: 10.1016/j.tiv.2011.03.011.
    1. Modestou MA, Manzel LJ, El-Mahdy S, Look DC. Inhibition of IFN-gamma-dependent antiviral airway epithelial defense by cigarette smoke. Respir Res. 2010;11:64. doi: 10.1186/1465-9921-11-64.
    1. Paes B, Steele S, Janes M, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada. Curr Med Res Opin. 2009;25(7):1585–1591. doi: 10.1185/03007990902929112.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir